vinnova 2012-11-01 samuel svensson peter ström carl m andersson
DESCRIPTION
Enabling rapid and simple radiolabeling of biologicals. RadTag multimodal bioimaging. Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson. Delivered 3 amyloid PET ligands to clinical testing. Nature (2008) 456 . RadTags simplify radiolabeling of biologicals. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/1.jpg)
22 Apr 2023 1
Vinnova 2012-11-01Samuel SvenssonPeter StrömCarl M Andersson
Enabling rapid and simple radiolabeling of biologicalsRadTag multimodal bioimaging
![Page 2: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/2.jpg)
Delivered 3 amyloid PET ligands to clinical testing
Nature (2008) 456
![Page 3: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/3.jpg)
RadTags simplify radiolabeling of biologicals
Enabling• Increased flexibility and specific binding• Stable binding – small tag size reduces interference with
target protein• PKPD studies with labeled proteins• Companion diagnostics• Potential for pre-targeting
”Agents and methods for visualising analytes ”PCT/EP2011/070172 IPR fully owned by BioPercept
![Page 4: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/4.jpg)
Biologicals are must have for pharmaSix out of 24 new approvals by the FDA were for biologicals in 2011-- share will increase; typical pharma ambition calls for 30-40% of pipeline
Radiolabeling within development of biologicals is very limited -- lack of generalised radiochemical methodology
Biosimilars market estimated at USD 4,000 million in 2017
Increasing demand for ability to monitor, visualise, perform PK studies
RadTags trigger a paradigm shift
See Statement of interest (back ups)
![Page 5: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/5.jpg)
FlAsH technology – a fluorescence labeling technology developed for live cell imaging (R Tsien Nobel prize 2008)
FlAsH-based protein detection available from
![Page 6: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/6.jpg)
RadTags bind to same consensus sequence as FlAsHNon-invasive, clean, targeted technique
![Page 7: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/7.jpg)
The CCPGCC tag can be incorporated by standard techniques– During peptide synthesis– Using Polymerase chain reaction (PCR)– Using commercially available cloning vectors from Life Technologies
PromotorGene
CCPGCC tag (in frame)
Expression vector
Easily constructed six-amino acid tags
![Page 8: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/8.jpg)
RadTags enable radiolabelling using different isotopes at the same site, Multimodal
Precursor for 18F, 121I, 125I, 131I,
Precursor for 13C, 14C, 11C, 3H, 19F
Flourescence
![Page 9: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/9.jpg)
Preclin summary
RadTag
• form rapid and covalent binding with CCPGCC-peptides• can rapidly be radiolabeled with [14C] & [3H]• bound to modifed a-MSH peptide retain pharmacological potency
![Page 10: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/10.jpg)
Commercial: InnovationskontorEtt LiUTechnical PoC: Prof Victor Hruby
![Page 11: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/11.jpg)
Ac-Nle-Asp-His-(D)Phe-Arg-Trp-Gly-Lys-Arg-Trp-Cys-Cys-Pro-Gly-Cys-Cys-Lys-Thr-Phe
Cheng et al J Nucl Med 2007; 48:987–994
PoC study: PET Melanoma
![Page 12: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/12.jpg)
RadTag-MSH [125I]NDP-a-MSH at hMCR1
RadTag-a-MSH retain same binding profile as a-MSH
PoC study: PET Melanoma
![Page 13: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/13.jpg)
Samuel Svensson, PhD• Professor of Pharmacology, LiU. Principal scientist
AstraZeneca R&D. Project leader PET ligand project 2004-2011 (AZD2184, 2995, 4694).
Chairman BioPercept
Peter Ström, MSc• Radiochemist with 20+ years experience within
AstraZeneca. CSO radiochemistry BioPercept
Carl M Andersson, PhD, associate professor• Organic chemist. Consultant with 20+ years experience
from senior managerial positions within biotech and pharma. CEO BioPercept
The Team
Åsa Wallin Affärsutvecklare InnovationskontorEtt LiU
![Page 14: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/14.jpg)
• Innovationsbron• Innovationskontoret, LiU, Maria Swartz• Competence Network AB, Södertälje• Prof Peter Konradsson, Organic Chemistry LiU
Financing and partners
![Page 15: Vinnova 2012-11-01 Samuel Svensson Peter Ström Carl M Andersson](https://reader037.vdocuments.us/reader037/viewer/2022103007/56815ccd550346895dcade99/html5/thumbnails/15.jpg)
www.biopercept.com